Effectiveness and safety of lidocaine use (review)

Author: Matveev A.V.¹, Krasheninnikov A.E.², Egorova E.A.³, Matveeva E.A.⁴

Abstract

Cardiac arrhythmias are complications of many cardiovascular diseases. They quite often acquire an unpredictable course and can result in the death. According to epidemiology data, heart rhythm disorders lead to the sudden death of about 200 thousand people in the Russian Federation annually. Sudden cardiac death overtakes about 400 thousand outpatients and hospital patients in the USA and about 280 thousand patients in Europe. The unpredictability of the occurrence and the transience of cardiac arrhythmias require urgent measures, including both non-pharmacological (electrical pacing, electrical shock therapy) and pharmacotherapeutic methods of treatment. This review is devoted to the study of the clinical features of the lidocaine infusions in patients with ventricular arrhythmias caused by an increase of the conducting cardiomyocytes automatism. The article presents the results of comparative effectiveness and safety studies of lidocaine prescribed for the treatment of ventricular tachycardia and ventricular fibrillation (in the absence of the effect of electro-impulse therapy). Lidocaine is compared with other antiarrhythmic drugs such as amiodarone, sotalol, bretylium tosylate and procainamide. Recommendations of ILCOR (International Committee for Interaction in the Field of Resuscitation), AHA (American Cardiology Association), ECS (European Cardiology Society) and European Society for Resuscitation for the treatment of refractory forms of ventricular arrhythmias and ventricular fibrillation are also discussed.

Key words

ventricular arrhythmias, ventricular fibrillation, lidocaine, antiarrhythmic drugs

References

Dumanskii Yu.V., Kabanova N.V., Verkhuletskii I.E., Sinepupov N.A., Osipov A.G., Sinepupov D.N. Acute circulatory disorders. Meditsina neotlozhnykh sostoyanii = Emergency medicine. 2012; (2): 71–87. [In Russian].
Shul'man V.A., Nikulina S.Yu., Kuzhel' D.A., Matyushin G.V. Primary arrhythmias:a training manual. Sovremennye problemy nauki i obrazovaniya = Modern problems of science and education. 2009; (1): 51-52. [In Russian].
Koster R.W., Walker R.G., Chapman F.W. Recurrent ventricular fibrillation during advanced life support care of patients with prehospital cardiac arrest. Resuscitation. 2008; 78 (3): 252–257. doi: 10.1016/j.resuscitation.2008.03.231
Link M.S., Berkow L.C., Kudenchuk P.J., Halperin H.R., Hess E.P., Moitra V.K., Neumar R.W., O'Neil B.J., Paxton J.H., Silvers S.M., White R.D., Yannopoulos D., Donnino M.W. Part 7: Adult advanced cardiovascular life support. Circulation. 2015; 132 (18): 444–464. doi: 10.1161/CIR.0000000000000261
McLeod S.L., Brignardello-Petersen R., Worster A., You J., Iansavichene A., Guyatt G., Cheskes S. Comparative effectiveness of antiarrhythmics for out-of-hospital cardiac arrest: A systematic review and network meta-analysis. Resuscitation. 2017; 121: 90–97. doi: 10.1016/j.resuscitation.2017.10.012
Soar J., Nolan J.P., Bottiger B.W., Perkins G.D., Lott G., Carli P., Pellis T., Sandroni C., Skrifvars M.B., Smith G.B., Sunde K., Deakin Ch.D., Adult advanced life support section Collaborators. European resuscitation council guidelines for resuscitation 2015. Section 3. Adult advanced life support. Resuscitation. 2015; 95: 100–147. doi: 10.1016/j.resuscitation.2015.07.016
White R.D., Russell J.K. Refibrillation, resuscitation and survival in out-of-hospital sudden cardiac arrest victims treated with biphasic automated external defibrillators. Resuscitation. 2002; 55 (1): 17–23. doi: 10.1016/S0300-9572(02)00194-6
Bunin Yu.A. Treatment for cardiac arrhythmias in pregnancy:efficiency and safety. Cardiosomatika = Cardiosomatics. 2013; 2 (4): 81–91. [In Russian].
Harrison E.E. Lidocaine in prehospital countershock refractory ventricular fibrillation. Ann Emerg Med. 1981; 10 (8): 420–423. doi: 10.1016/S0196-0644(81)80309-5
Herlitz J., Ekstrom L., Wennerblom B., Axelsson A., Bang A., Lindkvist J., Persson N.G., Holmberg S. Lidocaine in out-of-hospital ventricular fibrillation. Does it improve survival? Resuscitation. 1997; 33 (3): 199–205. doi: 10.1016/S0300-9572(96)01018-0
Kudenchuk P.J., Brown S.P., Daya M., Rea T., Nichol G., Morrison L.J., Leroux B., Vaillancourt C., Wittwer L., Callaway C.W., Christenson J., Egan D., Ornato J.P., Weisfeldt M.L., Stiell I.G., Idris A.H., Aufderheide To.P., Dunford J.V., Colella R.M., Vilke G.M., Brienza A.M., Desvigne-Nickens P., Gray P.C., Gray R., Seals N., Straight R., Dorian P., Resuscitation outcomes consortium investigators. Amiodarone, lidocaine, or placebo in out-of-hospital cardiac arrest. N. Engl. J. Med. 2016; 374: 1711–1722. doi: 10.1056/NEJMoa1514204
Kudenchuk P.J., Leroux B.G., Daya M., Rea T., Vaillancourt C., Morrison L.J., Callaway C.W., Christenson J., Ornato J.P., Dunford J.V., Wittwer L., Weisfeldt M.L., Aufderheide T.P., Vilke G.M., Idris A.H., Stiell I.G., Colella M.R., Kayea T., Egan D.A., Desvigne-Nickens P., Gray P., Gray R., Straight R., Dorian P. and the Resuscitation outcomes consortium investigators. Antiarrhythmic drugs for non-shockable-turned-shockable out-of-hospital cardiac arrest: The amiodarone, lidocaine or placebo study (ALPS). Circulation. 2017; 136 (22): 2119–2131. doi:10.1161/circulationaha.117.028624
Huang C.H., Yu P.H., Tsai M.S., Chuang P.Y., Wang T.D., Chiang C.Y., Chang W.Ti., Ma M.H.M., Tang C.H., Chen W.J. Acute hospital administration of amiodarone and/or lidocaine in shockable patients presenting with out-of-hospital cardiac arrest: A nationwide cohort study. Int. J. Cardiol. 2017; 227: 292–298. doi: 10.1016/j.ijcard.2016.11.101
Valdes S.O., Donoghue A.J., Hoyme D.B., Hammond R., Berg M.D., Berg R.A., Samson R.A., American heart association get with the guidelines-resuscitation investigators. Outcomes associated with amiodarone and lidocaine in the treatment of in-hospital pediatric cardiac arrest with pulseless ventricular tachycardia or ventricular fibrillation. Resuscitation. 2014; 85 (3): 381–386. doi: 10.1016/j.resuscitation.2013.12.008
Gaisenok O.V. The use of amiodarone in clinical practice: the problem of side effects. Ratsional'naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2010; 6 (6): 823-827. [In Russian].
Dorian P., Cass D., Schwartz B., Cooper R., Gelaznikas R., Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N. Engl. J. Med. 2002; 346 (12): 884–890. doi: 10.1056/NEJMoa013029
Rea R.S., Kane-Gill S.L., Rudis M.I., Seybert A.L., Oyen L.J., Ou N.N, Stauss J.L., Kirisci L., Idrees U., Henderson S.O. Comparing intravenous amiodarone or lidocaine, or both, outcomes for inpatients with pulseless ventricular arrhythmias. Crit. Care Med. 2006; 34 (6): 1617–1623. doi: 10.1097/01.CCM.0000217965.30554.D8
Tagami T., Matsui H., Tanaka C., Kaneko J., Kuno M., Ishinokami S., Unemoto K., Fushimi K., Yasunaga H. Amiodarone compared with lidocaine for out-of-hospital cardiac arrest with refractory ventricular fibrillation on hospital arrival: a nationwide database study. Cardiovasc. Drugs Ther. 2016; 30 (5): 485–491. doi: 10.1007/s10557-016-6689-7
Pollak P.T., Wee V., Al-Hazmi A., Martin J., Zarnke K.B. The use of amiodarone for in-hospital cardiac arrest at two tertiary care centres. Can. J. Cardiol. 2006; 22 (3): 199–202. doi: 10.1016/s0828-282x(06)70896-0
Volkov V.E. Possibilities of rational use of sotalol in cardiology. Atmosfera. Novosti kardiologii = Atmosphere. Cardiology news. 2009; (1): 22-24. [In Russian].
Ho D.S., Zecchin R.P., Richards D.A., Uther J.B., Ross D.L. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet. 1994; 344 (8914): 18-23. doi: 10.1016/s0140-6736(94)91048-0
Kovoor P., Love A., Hall J., Kruit R., Sadick N., Ho D., Adelstein B.A., Ross D.L. Randomized double-blind trial of sotalol versus lignocaine in out-of-hospital refractory cardiac arrest due to ventricular tachyarrhythmia. Intern. Med. J. 2005; 35 (9): 518–525. doi: 10.1111/j.1445-5994.2005.00896.x
Pantazopoulos I.N., Troupis G.T., Pantazopoulos C.N., Xanthos T.T. Nifekalant in the treatment of life-threatening ventricular tachyarrhythmias. World J. Cardiol. 2011; 3 (6): 169-176. doi: 10.4330/wjc.v3.i6.169
Shiga T., Tanaka K., Kato R., Amino M., Matsudo Y., Honda T., Sagara K., Takahashi A., Katoh T., Urashima M., Ogawa S., Takano T., Kasanuki H., Refractory VT/VF, Prospective evaluation to differentiate lidocaine efficacy from nifekalant (RELIEF) study investigators. Nifekalant versus lidocaine for in-hospital shock-resistant ventricular fibrillation or tachycardia. Resuscitation. 2010; 81 (1): 47–52. doi: 10.1016/j.resuscitation.2009.09.027
Tahara Y., Kimura K., Kosuge M., Ebina T., Sumita S., Hibi K., Toyama H., Kosuge T., Moriwaki Y., Suzuki N., Sugiyama M., Umemura S. Comparison of nifekalant and lidocaine for the treatment of shock-refractory ventricular fibrillation. Circ. J. 2006; 70 (4): 442–446. doi: 10.1253/circj.70.442
Kulik V.L., Burda I.Yu., Makienko N.V., Vlasenko O.A., Savchenko V.N. The clinical pharmacology of antiarrhythmic drugs class III. Visnyk Kharkivsʹkoho natsionalʹnoho universytetu imeni Vasilya Nazarovicha Karazina. Seriya "Medytsyna" = The Journal of V. N. Karazin Kharkiv National University. Series "Medicine". 2010; (19): 104-107. [In Russian].
Haynes R.E., Chinn T.L., Copass M.K., Cobb L.A. Comparison of bretylium tosylate and lidocaine in management of out of hospital ventricular fibrillation: A randomized clinical trial. Am. J. Cardiol. 1981; 48 (2): 353–356. doi: 10.1016/0002-9149(81)90619-6
Olson D.W., Thompson B.M., Darin J.C., Milbrath M.H. A randomized comparison study of bretylium tosylate and lidocaine in resuscitation of patients from out-of-hospital ventricular fibrillation in a paramedic system. Ann. Emerg. Med. 1984; 13 (9): 807–810. doi: 10.1016/s0196-0644(84)80444-8
Suvorov M.A., Suvorov A.V., Kaurov Ya.V., Gnelitsky G.I. Treatment of violations of rhythm and conductivity of heart at sharp poisoning of cardiotoxyc substanes. Zdorov'ye i obrazovaniye v XXI veke = Health and education in the 21^st century. 2013; 15 (1–4): 232–233. [In Russian].
Stiell I.G., Wells G.A., Hebert P.C., Laupacis A., Weitzman B.N. Association of drug therapy with survival in cardiac arrest: limited role of advanced cardiac life support drugs. Acad. Emerg. Med. 1995; 2 (4): 264–273. doi: 10.1111/j.1553-2712.1995.tb03220.x
Igarashi M., Fujino T., Toyoda M., Sugino K., Sasao K., Sasamoto S., Otsuka T., Kobayashi K., Okano Y., Yosiwara K., Koyama N. Defibrillation effects of intravenous nifekalant in patients with out-of-hospital ventricular fibrillation. Pacing Clin. Electrophysiol. 2005; 28 (1): 155–157. doi: 10.1111/j.1540-8159.2005.00043.x
Chowdhury A., Fernandes B., Melhuish T.M., White L.D. Antiarrhythmics in cardiac arrest: A systematic review and meta-analysis. Heart Lung Circ. 2018; 27 (3): 280–290. doi: 10.1016/j.hlc.2017.07.004
Ali M.U., Fitzpatrick-Lewis D., Kenny M., Raina P., Atkins D.L., Soar J., Nolan J., Ristagno G., Sherifali D. Effectiveness of antiarrhythmic drugs for shockable cardiac arrest: A systematic review. Resuscitation. 2018; 132: 63–72. doi: 10.1016/j.resuscitation.2018.08.025
Khan S.U., Winnicka L., Sallem M.A., Rahman H., Rehman N. Amiodarone, lidocaine, magnesium or placebo in shock refractory ventricular arrhythmia: A Bayesian network meta-analysis. Heart Lung. 2017; 46 (6): 417–424. doi: 10.1016/j.hrtlng.2017.09.001
Suzuki M., Nagahori W., Mizukami A., Matsumura A., Hashimoto Y. A multicenter observational study of the effectiveness of antiarrhythmic agents in ventricular arrhythmias: A propensity-score adjusted analysis. J. Arrhythm. 2016; 32 (3): 186-190. doi: 10.1016/j.joa.2016.01.004
Panchal A.R., Berg K.M., Kudenchuk P.J., Rios M.D., Hirsch K.G., Link M.S., Kurz M.C., Chan P.S., Cabañas J.G., Morley P.T., Hazinski M.F., Donnino M.W. 2018 American heart association focused update on advanced cardiovascular life support use of antiarrhythmic drugs during and immediately after cardiac arrest: An update to the American heart association guidelines for cardiopulmonary resuscitation and em. Circulation. 2018; 138 (23): 740-749. doi: 10.1161/CIR.0000000000000613

About Authors (Correspondence):

Egorova E.A., e-mail: elena212007@rambler.ru

Full Text

snmzh_6-2020_matveev_i_dr.pdf

Received: 24/12/2020

Accepted: 24/12/2020